AstraZeneca's Kidney Cancer Treatment Shows Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: seekingalpha
- Clinical Trial Results: AstraZeneca's Imfinzi combined with Imjudo, Lenvima, and TACE demonstrated significant improvement in progression-free survival compared to TACE alone, with a median progression-free survival of 13 months for the STRIDE regimen versus 9.8 months for TACE, indicating the efficacy of the new treatment.
- Risk Reduction: The interim analysis revealed that the STRIDE regimen combined with Lenvima and TACE led to a 30% reduction in the risk of disease progression or death compared to TACE alone, providing a more effective treatment option for kidney cancer patients and potentially changing clinical treatment standards.
- Survival Rate Trend: A positive trend was observed in overall survival as a secondary endpoint with STRIDE plus Lenvima and TACE compared to TACE alone, further supporting the potential advantages of this combination therapy.
- Market Outlook: AstraZeneca's innovative treatment options in the kidney cancer space not only enhance the competitiveness of its product portfolio but may also drive future revenue growth, particularly in the expanding kidney cancer treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 177.890
Low
157.61
Averages
213.64
High
252.18
Current: 177.890
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AstraZeneca Receives FDA Priority Review for New Drug
- FDA Review Progress: AstraZeneca announced that its new drug has been granted priority review status by the U.S. Food and Drug Administration (FDA), which will expedite the drug's approval process and is expected to positively impact the company's future revenue growth.
- Market Potential: The priority review indicates that the FDA will assess the drug's safety and efficacy more quickly, and if approved, it will provide AstraZeneca with a significant market advantage in a competitive pharmaceutical landscape, especially given the growing demand in the therapeutic area.
- R&D Investment Returns: This priority review is a result of AstraZeneca's ongoing investment in new drug development, and successful approval will enhance the company's reputation in the innovative drug sector, potentially attracting more investor interest in its R&D pipeline.
- Strategic Implications: The FDA's priority review not only boosts AstraZeneca's market competitiveness but may also lead to higher shareholder returns, further solidifying its leadership position in the global pharmaceutical industry.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Future Outlook for Obesity Medications
- Intensifying Market Competition: At the American Diabetes Association Scientific Sessions, Eli Lilly and Novo Nordisk showcased their new GLP-1 drugs, with Novo Nordisk's Wegovy pill achieving over 3 million prescriptions within five months of launch, indicating the potential of oral medications to attract more patients to weight-loss treatments.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data on their respective GLP-1 pills, which, if successful in Phase 3 trials, are expected to hit the market by 2029, further enriching the options available to meet the growing demand for obesity treatments.
- Innovative Treatment Frequency: Pfizer's drug, acquired through its $10 billion purchase of Metsera, shows potential for monthly injections, while Amgen is testing a drug that could be administered quarterly, significantly improving patient adherence and reducing the burden of weekly injections.
- Exploration of Emerging Therapies: Zealand Pharma's petrelintide drug demonstrated an average weight loss of nearly 11% in mid-stage trials, which, while less effective than existing medications, had fewer side effects, leading the CEO to believe that this could spark strong demand for new therapies and potentially reshape the obesity treatment market.
See More
AstraZeneca's Truqap Approved by FDA for Prostate Cancer Treatment
- First Targeted Treatment: AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved as the first targeted therapy for PTEN-deficient metastatic prostate cancer in the US, representing a significant advancement in treatment options.
- FDA Companion Diagnostic: The FDA also authorized a companion diagnostic test to detect PTEN deficiency in prostate adenocarcinoma patients, ensuring eligible individuals can be accurately identified for Truqap treatment, thereby enhancing treatment precision.
- EU Regulatory Review: A regulatory application for the Truqap regimen in this indication is currently under review in the European Union, supported by data from the CAPItello-281 Phase III trial, which demonstrated the efficacy and safety of the combination in patients with PTEN-deficient metastatic prostate cancer.
- Market Reaction: AstraZeneca's stock closed at $178.75, down $3.53 (1.94%) in regular trading, but gained $2.05 (1.15%) in after-hours trading, indicating a positive market response to the new treatment approval.
See More
AstraZeneca's TRUQAP Approved for Prostate Cancer Treatment
- Clinical Trial Results: The CAPItello-281 trial demonstrated that the combination of TRUQAP and abiraterone reduced the risk of radiographic disease progression or death by 19%, significantly increasing the median radiographic progression-free survival (rPFS) to 33.2 months, indicating the combination's critical clinical significance for treating PTEN-deficient prostate cancer patients.
- FDA Approval: TRUQAP has been approved by the US FDA as the first targeted treatment for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, marking a significant advancement in this field and is expected to improve patients' quality of life and disease prognosis.
- Market Demand: Approximately 200,000 patients globally are diagnosed with PTEN-deficient metastatic prostate cancer each year, with about 35,000 in the US, and the launch of TRUQAP will provide new hope for these patients urgently needing biomarker-directed therapies, addressing the pressing market demand for effective treatments.
- Safety Analysis: In the CAPItello-281 trial, 67% of patients experienced grade 3 or higher adverse events, with the most common being rash (12.3%) and hyperglycemia (10.3%), indicating the need for close monitoring of patient safety during TRUQAP treatment to ensure sustainable therapy.
See More
AstraZeneca's Truqap Receives FDA Label Expansion Approval
- Label Expansion: AstraZeneca's anti-tumor agent Truqap (capivasertib) has received FDA approval for label expansion, allowing its use in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Evidence: The latest approval is backed by late-stage trial data indicating that Truqap, when combined with abiraterone and androgen deprivation therapy, reduces the risk of radiographic disease progression or death by 19% in newly diagnosed PTEN-deficient metastatic prostate cancer, showcasing its therapeutic efficacy.
- Market Potential: This approval expands Truqap's indications in the U.S. market beyond its previous use as a late-line therapy for a specific type of breast cancer, potentially creating new revenue streams for AstraZeneca and solidifying its position in the oncology market.
- FDA Support: Last month, an FDA advisory committee voted 7-1 in favor of recommending the approval, reflecting broad recognition of its clinical effectiveness and providing strong support for AstraZeneca's future drug development and market promotion efforts.
See More
AstraZeneca Receives FDA Priority Review for New Drug
- FDA Review Progress: AstraZeneca announced that its new drug has been granted priority review status by the U.S. Food and Drug Administration (FDA), which will expedite the drug's approval process and is expected to positively impact the company's future revenue growth.
- Market Potential: The priority review indicates that the FDA will assess the drug's safety and efficacy more quickly, and if approved, it will provide AstraZeneca with a significant market advantage in a competitive pharmaceutical landscape, especially given the growing demand in the therapeutic area.
- R&D Investment Returns: This priority review is a result of AstraZeneca's ongoing investment in new drug development, and successful approval will enhance the company's reputation in the innovative drug sector, potentially attracting more investor interest in its R&D pipeline.
- Strategic Implications: The FDA's priority review not only boosts AstraZeneca's market competitiveness but may also lead to higher shareholder returns, further solidifying its leadership position in the global pharmaceutical industry.
See More
Future Outlook for Obesity Drugs Market
- Intensifying Market Competition: At the conference in New Orleans, Eli Lilly and Novo Nordisk showcased their GLP-1 drugs, with Novo's Wegovy prescriptions exceeding 3 million within five months of launch, indicating that oral medications are attracting more consumers and could reshape the weight loss drug market.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data, and if their GLP-1 drugs succeed in Phase 3 trials, they are expected to hit the market by 2029, further enriching market options and intensifying competition.
- Innovative Administration Methods: Pfizer's new drug shows potential for monthly administration, which could be more convenient than current weekly injections, while Amgen is testing a drug that could be administered monthly or quarterly, aiming to enhance patient adherence to treatment.
- Future Market Outlook: With approximately 2.5 billion people globally classified as overweight and 890 million as obese, the competition will intensify as new drugs continue to emerge, while Lilly and Novo are also working to improve insurance coverage for GLP-1 drugs, which is expected to attract more patients.
See More
Future Outlook for Obesity Medications
- Intensifying Market Competition: At the American Diabetes Association Scientific Sessions, Eli Lilly and Novo Nordisk showcased their new GLP-1 drugs, with Novo Nordisk's Wegovy pill achieving over 3 million prescriptions within five months of launch, indicating the potential of oral medications to attract more patients to weight-loss treatments.
- New Drug Development Updates: Structure Therapeutics and AstraZeneca shared mid-stage data on their respective GLP-1 pills, which, if successful in Phase 3 trials, are expected to hit the market by 2029, further enriching the options available to meet the growing demand for obesity treatments.
- Innovative Treatment Frequency: Pfizer's drug, acquired through its $10 billion purchase of Metsera, shows potential for monthly injections, while Amgen is testing a drug that could be administered quarterly, significantly improving patient adherence and reducing the burden of weekly injections.
- Exploration of Emerging Therapies: Zealand Pharma's petrelintide drug demonstrated an average weight loss of nearly 11% in mid-stage trials, which, while less effective than existing medications, had fewer side effects, leading the CEO to believe that this could spark strong demand for new therapies and potentially reshape the obesity treatment market.
See More
AstraZeneca's Truqap Approved by FDA for Prostate Cancer Treatment
- First Targeted Treatment: AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved as the first targeted therapy for PTEN-deficient metastatic prostate cancer in the US, representing a significant advancement in treatment options.
- FDA Companion Diagnostic: The FDA also authorized a companion diagnostic test to detect PTEN deficiency in prostate adenocarcinoma patients, ensuring eligible individuals can be accurately identified for Truqap treatment, thereby enhancing treatment precision.
- EU Regulatory Review: A regulatory application for the Truqap regimen in this indication is currently under review in the European Union, supported by data from the CAPItello-281 Phase III trial, which demonstrated the efficacy and safety of the combination in patients with PTEN-deficient metastatic prostate cancer.
- Market Reaction: AstraZeneca's stock closed at $178.75, down $3.53 (1.94%) in regular trading, but gained $2.05 (1.15%) in after-hours trading, indicating a positive market response to the new treatment approval.
See More
AstraZeneca's TRUQAP Approved for Prostate Cancer Treatment
- Clinical Trial Results: The CAPItello-281 trial demonstrated that the combination of TRUQAP and abiraterone reduced the risk of radiographic disease progression or death by 19%, significantly increasing the median radiographic progression-free survival (rPFS) to 33.2 months, indicating the combination's critical clinical significance for treating PTEN-deficient prostate cancer patients.
- FDA Approval: TRUQAP has been approved by the US FDA as the first targeted treatment for PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer, marking a significant advancement in this field and is expected to improve patients' quality of life and disease prognosis.
- Market Demand: Approximately 200,000 patients globally are diagnosed with PTEN-deficient metastatic prostate cancer each year, with about 35,000 in the US, and the launch of TRUQAP will provide new hope for these patients urgently needing biomarker-directed therapies, addressing the pressing market demand for effective treatments.
- Safety Analysis: In the CAPItello-281 trial, 67% of patients experienced grade 3 or higher adverse events, with the most common being rash (12.3%) and hyperglycemia (10.3%), indicating the need for close monitoring of patient safety during TRUQAP treatment to ensure sustainable therapy.
See More
AstraZeneca's Truqap Receives FDA Label Expansion Approval
- Label Expansion: AstraZeneca's anti-tumor agent Truqap (capivasertib) has received FDA approval for label expansion, allowing its use in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Evidence: The latest approval is backed by late-stage trial data indicating that Truqap, when combined with abiraterone and androgen deprivation therapy, reduces the risk of radiographic disease progression or death by 19% in newly diagnosed PTEN-deficient metastatic prostate cancer, showcasing its therapeutic efficacy.
- Market Potential: This approval expands Truqap's indications in the U.S. market beyond its previous use as a late-line therapy for a specific type of breast cancer, potentially creating new revenue streams for AstraZeneca and solidifying its position in the oncology market.
- FDA Support: Last month, an FDA advisory committee voted 7-1 in favor of recommending the approval, reflecting broad recognition of its clinical effectiveness and providing strong support for AstraZeneca's future drug development and market promotion efforts.
See More
